
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. reported record total revenues of $12.1 million for the quarter, reflecting a remarkable 154% year-over-year increase and surpassing consensus estimates. The company's gross margin improved to 71%, up from 65% in the previous quarter, indicating enhanced profitability. Additionally, with a robust pipeline growth of new patient candidates and a projected revenue increase to between $50-53 million for 2025, Myomo is well-positioned for continued financial success and expansion in the wearable medical robotics market.
Bears say
Myomo Inc's backlog of insurance-authorized sales decreased to 272 from 316 in the previous quarter, indicating potential challenges in demand for its myoelectric orthosis products. Furthermore, the company remains vulnerable to several substantial risks, including liquidity issues, regulatory hurdles, and competitive pressures, which could impede its ability to achieve future profitability and sustain growth. Although Myomo reported a net loss of $0.01 per share, which was better than the consensus estimate, the broader financial environment and underlying operational risks contribute to a negative outlook.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares